Sugi Predict

Sugi Predict / Targets / CYP24A1

CYP24A1

1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial · Q07973 · CYP24A1 on Sugi Atlas →

14,590 patent compounds predicted against CYP24A1, 9,669 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1503385 SCHEMBL1503385 1.00 19/20
SCHEMBL1503388 SCHEMBL1503388 1.00 19/20
SCHEMBL410598 SCHEMBL410598 0.54 11/20
SCHEMBL2351781 SCHEMBL2351781 0.50 10/20
SCHEMBL2263898 SCHEMBL2263898 0.43 10/20
SCHEMBL630429 SCHEMBL630429 0.57 8/20
SCHEMBL2163893 SCHEMBL2163893 0.62 7/20
SCHEMBL2163897 SCHEMBL2163897 0.62 7/20
SCHEMBL1325290 SCHEMBL1325290 0.31 7/20
SCHEMBL229052 SCHEMBL229052 0.79 6/20
SCHEMBL2877992 SCHEMBL2877992 0.76 6/20
SCHEMBL630276 SCHEMBL630276 0.70 6/20
SCHEMBL2552312 SCHEMBL2552312 0.61 6/20
SCHEMBL879971 SCHEMBL879971 0.58 6/20
SCHEMBL630841 SCHEMBL630841 0.56 6/20
SCHEMBL2440274 SCHEMBL2440274 0.56 6/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1813880) 0.54 6/20
SCHEMBL1372978 SCHEMBL1372978 0.54 6/20
SCHEMBL972021 SCHEMBL972021 0.53 6/20
SCHEMBL2419258 SCHEMBL2419258 0.52 6/20

Clinical trials — most relevant to CYP24A1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Single High Dose of Cholecalciferol on Serum Metabolites of Vitamin D PHASE4COMPLETED
Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis PHASE4UNKNOWN
Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism PHASE4COMPLETED
Efficacy of Fractional CO2 Laser as a Mono- or Adjuvant Therapy for Alopecia Areata PHASE4UNKNOWN
Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression PHASE4UNKNOWN
Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea PHASE3COMPLETED
Vitamin D Supplementation in Cirrhotic Patients PHASE2COMPLETED
Cholecalciferol on Depressive Symptoms in Type 2 Diabetes Mellitus Patients PHASE2UNKNOWN
Vitamin D Deficiency Treatment Outcomes After Non-ST-Segment Elevation Myocardial Infarction PHASE2UNKNOWN
Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease PHASE1COMPLETED
Hypercalcemia After Paraffin Oil Injection nanRECRUITING
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
Genetic, Dietary and Environmental Influences on Vitamin D Metabolism nanCOMPLETED
Replacement of Vitamin D in Patients With Active Tuberculosis nanCOMPLETED
Serum and Semen Vitamin D Level With Semen Parameters nanUNKNOWN
Non-inferiority RCT on Fish Waste-Derived vs. Synthetic Vitamin D Supplementation in Healthy Adults With Suboptimal Vitamin D Levels nanNOT_YET_RECRUITING
Vitamin D and the Free Hormone Hypothesis nanCOMPLETED
The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients nanNOT_YET_RECRUITING
Correlation Between Vitamin D Serum Level and Early Implant Failure nanCOMPLETED
The Efficacy of Nigella Sativa Versus VitaminD3 as Supplement Therapy in Coronavirus Disease 2019 (COVID-19) nanUNKNOWN
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer nanCOMPLETED
Vitamin D Analog in Vitamin D 24-hydroxylase Deficiency nanRECRUITING
The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bone Mineral Density nanRECRUITING
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements nanCOMPLETED
Safety and Bioefficacy of Vitamin D2 and Vitamin D3 nanCOMPLETED
The Effect of Vitamin D Supplementation on Arterial Stiffness in Diabetic Patients nanCOMPLETED
Prognostic Value of Vitamin D Levels in Egyptian Females With Breast Cancer nanUNKNOWN
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease nanCOMPLETED
Is There Association Between Vitamin D Levels And Insulin Resistance In Polycystic Ovary Syndrome? nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CYP24A1 binder may also engage these)

ProteinNameSimilarity
Q64441 — 0.999 Q64441 →
Q09128 — 0.998 Q09128 →
P48416 — 0.994 P48416 →
P0DOX0 — 0.992 P0DOX0 →
A8WGA0 — 0.991 A8WGA0 →
O44220 — 0.989 O44220 →
Q9V8M2 — 0.989 Q9V8M2 →
Q9VVR9 — 0.989 Q9VVR9 →
Q7KR10 — 0.986 Q7KR10 →
Q8HYM9 — 0.985 Q8HYM9 →
CYP17A1 Steroid 17-alpha-hydroxylase/17,20 lyase 0.984 landscape →
A0A410UD22 — 0.983 A0A410UD22 →
Q8HYN1 — 0.983 Q8HYN1 →
Q8HYN0 — 0.983 Q8HYN0 →
Q95328 — 0.983 Q95328 →
O18635 — 0.981 O18635 →
P30437 — 0.981 P30437 →
Q9GLD2 — 0.981 Q9GLD2 →
Q4G0S4 — 0.981 Q4G0S4 →
P82713 — 0.981 P82713 →
Q9N0U7 — 0.981 Q9N0U7 →
Q2XVA1 — 0.981 Q2XVA1 →
P82712 — 0.981 P82712 →
Q29497 — 0.980 Q29497 →
P70091 — 0.980 P70091 →
Q9GMC8 — 0.980 Q9GMC8 →
P05185 — 0.980 P05185 →
Q6JD68 — 0.979 Q6JD68 →
P27786 — 0.979 P27786 →
P90771 — 0.979 P90771 →